{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:42Z","timestamp":1792783302695,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82403871"],"award-info":[{"award-number":["82403871"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shanghai Pu Jiang Program","award":["23PJ1401400"],"award-info":[{"award-number":["23PJ1401400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03384-6","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:53:19Z","timestamp":1789451599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-0953","authenticated-orcid":false,"given":"Xuefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"3","key":"3384_CR1","doi-asserted-by":"publisher","first-page":"152341","DOI":"10.1016\/j.seminoncol.2025.152341","volume":"52","author":"SP Pradhan","year":"2025","unstructured":"Pradhan SP, Gadnayak A, Pradhan SK, Epari V. Epidemiology and prevention of gastric cancer: A comprehensive review. Semin Oncol. 2025;52(3):152341. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152341.","journal-title":"Semin Oncol"},{"issue":"10494","key":"3384_CR2","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, et al. Gastric cancer. Lancet Lond Engl. 2025;405(10494):2087\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(25)00052-2.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"3384_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44(1):127\u201372. https:\/\/doi.org\/10.1002\/cac2.12516.","journal-title":"Cancer Commun"},{"issue":"5","key":"3384_CR4","doi-asserted-by":"publisher","first-page":"152369","DOI":"10.1016\/j.seminoncol.2025.152369","volume":"52","author":"I Dadi","year":"2025","unstructured":"Dadi I, Mazard T, Schmitt L-M, Chastel T, Turtoi A, Poul M-A, et al. Antibody treatments for digestive cancers: Past, present, and future. Semin Oncol. 2025;52(5):152369. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152369.","journal-title":"Semin Oncol"},{"issue":"1","key":"3384_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamasurg.2021.5104","volume":"157","author":"C Huang","year":"2022","unstructured":"Huang C, Liu H, Hu Y, Sun Y, Su X, Cao H, et al. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer. JAMA Surg. 2022;157(1):9. https:\/\/doi.org\/10.1001\/jamasurg.2021.5104.","journal-title":"JAMA Surg"},{"issue":"10111","key":"3384_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"issue":"10142","key":"3384_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, Di Bartolomeo M, Mandal\u00e0 M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"issue":"5","key":"3384_CR8","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. JAMA Oncol. 2018;4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3384_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li Y, Zheng Y, Huang J, Nie R-C, Wu Q-N, Zuo Z, et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut. 2025;74(3):350\u201363. https:\/\/doi.org\/10.1136\/gutjnl-2024-333617.","journal-title":"Gut"},{"key":"3384_CR10","doi-asserted-by":"publisher","first-page":"1667589","DOI":"10.3389\/fonc.2025.1667589","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang J, Wang Y, Ma H, Li Y, Hou J, Li J, et al. CLIC6\u2019s role in cancer: from broad analysis to breast cancer validation. Front Oncol. 2025;15:1667589. https:\/\/doi.org\/10.3389\/fonc.2025.1667589.","journal-title":"Front Oncol"},{"key":"3384_CR11","doi-asserted-by":"publisher","first-page":"1670526","DOI":"10.3389\/fonc.2025.1670526","volume":"15","author":"D Elihamu","year":"2025","unstructured":"Elihamu D, Li Y, Wang Y, Cui H, Xing Y, Peng H, et al. CORO1A: a pan-cancer prognosis, diagnostic and immune biomarker based on breast cancer validation. Front Oncol. 2025;15:1670526. https:\/\/doi.org\/10.3389\/fonc.2025.1670526.","journal-title":"Front Oncol"},{"key":"3384_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2147\/BCTT.S553681","volume":"17","author":"Y Gou","year":"2025","unstructured":"Gou Y, Li Y, Wang Y, Ma H, Li H, Geni R, et al. Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker. Breast Cancer. 2025;17:1439\u201361. https:\/\/doi.org\/10.2147\/BCTT.S553681.","journal-title":"Breast Cancer"},{"key":"3384_CR13","doi-asserted-by":"publisher","first-page":"1770711","DOI":"10.3389\/fimmu.2026.1770711","volume":"17","author":"Y Wang","year":"2026","unstructured":"Wang Y, Zhang Y, Li Y, Ma H, Zhao J, Ismtula D, et al. The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification. Front Immunol. 2026;17:1770711. https:\/\/doi.org\/10.3389\/fimmu.2026.1770711.","journal-title":"Front Immunol"},{"issue":"10","key":"3384_CR14","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"issue":"1","key":"3384_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/imm.70038","volume":"177","author":"B Cai","year":"2026","unstructured":"Cai B, Feng X, Luo S, Nurbahati A, Cui H, Peng T, et al. 5-FU Resistance Facilitates Immune Evasion in Esophageal Squamous Cell Carcinoma Through ADAM10-Mediated PD-L1 Shedding and Tumour Microenvironment Remodelling. Immunology. 2026;177(1):170\u201384. https:\/\/doi.org\/10.1111\/imm.70038.","journal-title":"Immunology"},{"issue":"19","key":"3384_CR16","doi-asserted-by":"publisher","first-page":"e122467","DOI":"10.1172\/jci.insight.122467","volume":"3","author":"R Yossef","year":"2018","unstructured":"Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018;3(19):e122467. https:\/\/doi.org\/10.1172\/jci.insight.122467.","journal-title":"JCI Insight"},{"issue":"12","key":"3384_CR17","doi-asserted-by":"publisher","first-page":"e005443","DOI":"10.1136\/jitc-2022-005443","volume":"10","author":"J Palomero","year":"2022","unstructured":"Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, D\u00edaz-G\u00f3mez J, Grases D, et al. Biomarkers of tumor-reactive CD4\u2009+\u2009and CD8\u2009+\u2009TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022;10(12):e005443. https:\/\/doi.org\/10.1136\/jitc-2022-005443.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3384_CR18","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci. 2007;104(9):3360\u20135. https:\/\/doi.org\/10.1073\/pnas.0611533104.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3384_CR19","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1053\/j.gastro.2018.08.030","volume":"155","author":"H-D Kim","year":"2018","unstructured":"Kim H-D, Song G-W, Park S, Jung MK, Kim MH, Kang HJ, et al. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8\u2009+\u2009T Cells and Features of Hepatocellular Carcinoma. Gastroenterology. 2018;155(6):1936\u2013e195017. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.030.","journal-title":"Gastroenterology"},{"issue":"1","key":"3384_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-016-0539-x","volume":"15","author":"Y Li","year":"2016","unstructured":"Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15(1):55. https:\/\/doi.org\/10.1186\/s12943-016-0539-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"3384_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40425-019-0499-y","volume":"7","author":"JCT Joe Yeong, Lim","year":"2019","unstructured":"Joe Yeong, Lim JCT, Lee B, Li H, Ong CCH, Thike AA, et al. Prognostic value of CD8\u2009+\u2009PD-1\u2009+\u2009immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer. 2019;7(1):34. https:\/\/doi.org\/10.1186\/s40425-019-0499-y.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3384_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/cancers13061297","volume":"13","author":"L Seifert","year":"2021","unstructured":"Seifert L, Plesca I, M\u00fcller L, Sommer U, Heiduk M, von Renesse J, et al. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Cancers. 2021;13(6):1297. https:\/\/doi.org\/10.3390\/cancers13061297.","journal-title":"Cancers"},{"issue":"8","key":"3384_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/jpm11080749","volume":"11","author":"G Rhyner Agocs","year":"2021","unstructured":"Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galv\u00e1n JA, Lugli A, et al. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J Pers Med. 2021;11(8):749. https:\/\/doi.org\/10.3390\/jpm11080749.","journal-title":"J Pers Med"},{"issue":"2","key":"3384_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.21037\/tlcr-20-1019","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chen P, Wang H, Wu S, Zhao S, He Y, et al. The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2021;10(2):1029\u201338. https:\/\/doi.org\/10.21037\/tlcr-20-1019.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"3384_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.21147\/j.issn.1000-9604.2023.03.04","volume":"35","author":"C Chen","year":"2023","unstructured":"Chen C, Li Y. Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies. Chin J Cancer Res. 2023;35(3):245. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2023.03.04.","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"3384_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, M\u00fcller P, Herzig P, Roller A, Belousov A, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol Res. 2015;3(12):1344\u201355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0097.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"3384_CR27","doi-asserted-by":"publisher","first-page":"e002836","DOI":"10.1136\/jitc-2021-002836","volume":"9","author":"P Wang","year":"2021","unstructured":"Wang P, Chen Y, Long Q, Li Q, Tian J, Liu T, et al. Increased coexpression of PD-L1 and TIM3\/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. J Immunother Cancer. 2021;9(10):e002836. https:\/\/doi.org\/10.1136\/jitc-2021-002836.","journal-title":"J Immunother Cancer"},{"key":"3384_CR28","doi-asserted-by":"publisher","first-page":"110207","DOI":"10.1016\/j.intimp.2023.110207","volume":"119","author":"A Meyiah","year":"2023","unstructured":"Meyiah A, Mahmoodi Chalbatani G, Al-Mterin MA, Malekraeisi MA, Murshed K, Elkord E. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8\u2009+\u2009T cells showed synergistic effects on improved disease-free survival in treatment-na\u00efve CRC patients. Int Immunopharmacol. 2023;119:110207. https:\/\/doi.org\/10.1016\/j.intimp.2023.110207.","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"3384_CR29","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. J Clin Oncol. 2024;42(17):2080\u201393. https:\/\/doi.org\/10.1200\/JCO.23.01636.","journal-title":"J Clin Oncol"},{"key":"3384_CR30","doi-asserted-by":"publisher","unstructured":"Lucchesi FR, Aredes ND. The Cancer Genome Atlas Stomach Adenocarcinoma Collection (TCGA-STAD) (Version 3). 2016; https:\/\/doi.org\/10.7937\/K9\/TCIA.2016.GDHL9KIM","DOI":"10.7937\/K9\/TCIA.2016.GDHL9KIM"},{"key":"3384_CR31","doi-asserted-by":"publisher","unstructured":"Yoon S-J, Park J, Shin Y, Choi Y, Park SW, Kang S-G, et al. Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB\/c nude mice model. BMC Cancer. 2020;20(1). https:\/\/doi.org\/10.1186\/s12885-020-06814-4.","DOI":"10.1186\/s12885-020-06814-4"},{"issue":"9","key":"3384_CR32","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"issue":"8","key":"3384_CR33","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71\u201371. https:\/\/doi.org\/10.1093\/nar\/gkv1507.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3384_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14(1):7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"3384_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"1","key":"3384_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13059-022-02828-2","volume":"23","author":"B Kang","year":"2022","unstructured":"Kang B, Camps J, Fan B, Jiang H, Ibrahim MM, Hu X, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol. 2022;23(1):265. https:\/\/doi.org\/10.1186\/s13059-022-02828-2.","journal-title":"Genome Biol"},{"issue":"5","key":"3384_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411\u201320. https:\/\/doi.org\/10.1038\/nbt.4096.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3384_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"224","author":"M Ashburner","year":"2023","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1):25\u20139. https:\/\/doi.org\/10.1038\/75556.","journal-title":"Genetics"},{"issue":"43","key":"3384_CR39","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"3384_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267\u201373. https:\/\/doi.org\/10.1038\/ng1180.","journal-title":"Nat Genet"},{"key":"3384_CR41","doi-asserted-by":"publisher","unstructured":"Wang M, Du Q, Jin J, Wei Y, Lu Y, Li Q, et al. LAG3 and its emerging role in cancer immunotherapy. Clin Transl Med. 2021;11(3). https:\/\/doi.org\/10.1002\/ctm2.365.","DOI":"10.1002\/ctm2.365"},{"issue":"1","key":"3384_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024;42(1):179\u2013206. https:\/\/doi.org\/10.1146\/annurev-immunol-090222-110914.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3384_CR43","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41416-022-01939-8","volume":"127","author":"K Yu","year":"2022","unstructured":"Yu K, Gu Y, Zhang P, Fang H, Cao Y, Wang J, et al. Intratumoral PD-1\u2009+\u2009CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer. Br J Cancer. 2022;127(9):1709\u201317. https:\/\/doi.org\/10.1038\/s41416-022-01939-8.","journal-title":"Br J Cancer"},{"issue":"3","key":"3384_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10120-023-01364-7","volume":"26","author":"J Choo","year":"2023","unstructured":"Choo J, Kua LF, Soe MY, Asuncion BR, Tan BKJ, Teo CB, et al. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2023;26(3):393\u2013404. https:\/\/doi.org\/10.1007\/s10120-023-01364-7.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"1","key":"3384_CR45","doi-asserted-by":"publisher","first-page":"1954761","DOI":"10.1080\/2162402X.2021.1954761","volume":"10","author":"Y Park","year":"2021","unstructured":"Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn S-H, et al. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. OncoImmunology. 2021;10(1):1954761. https:\/\/doi.org\/10.1080\/2162402X.2021.1954761.","journal-title":"OncoImmunology"},{"issue":"1","key":"3384_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43(1):1\u20139. https:\/\/doi.org\/10.1080\/25785826.2019.1698261.","journal-title":"Immunol Med"},{"issue":"5","key":"3384_CR47","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8\u2009+\u2009tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246\u201359. https:\/\/doi.org\/10.1172\/JCI73639.","journal-title":"J Clin Invest"},{"issue":"1","key":"3384_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","volume":"14","author":"JM Mazet","year":"2023","unstructured":"Mazet JM, Mahale JN, Tong O, Watson RA, Lechuga-Vieco AV, Pirgova G, et al. IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. Nat Commun. 2023;14(1):321. https:\/\/doi.org\/10.1038\/s41467-023-35948-9.","journal-title":"Nat Commun"},{"issue":"4","key":"3384_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178(4):933\u2013e94814. https:\/\/doi.org\/10.1016\/j.cell.2019.07.019.","journal-title":"Cell"},{"issue":"10","key":"3384_CR50","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s11427-025-2958-3","volume":"68","author":"D Liu","year":"2025","unstructured":"Liu D, Zhang T, Sun Q, Cai D, Lou Y, Wang G, et al. Selective expansion of TCF7-expressing tumor-reactive T cell subpopulations during ovarian tumor-infiltrating T cell production ex vivo. Sci China Life Sci. 2025;68(10):2891\u2013907. https:\/\/doi.org\/10.1007\/s11427-025-2958-3.","journal-title":"Sci China Life Sci"},{"issue":"7","key":"3384_CR51","doi-asserted-by":"publisher","first-page":"e008739","DOI":"10.1136\/jitc-2023-008739","volume":"12","author":"SG De Le\u00f3n-Rodr\u00edguez","year":"2024","unstructured":"De Le\u00f3n-Rodr\u00edguez SG, Aguilar-Flores C, Gaj\u00f3n JA, Ju\u00e1rez-Flores \u00c1, Mantilla A, Gerson-Cwilich R, et al. TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response. J Immunother Cancer. 2024;12(7):e008739. https:\/\/doi.org\/10.1136\/jitc-2023-008739.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3384_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41577-021-00563-6","volume":"22","author":"X Zhao","year":"2022","unstructured":"Zhao X, Shan Q, Xue H-H. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2022;22(3):147\u201357. https:\/\/doi.org\/10.1038\/s41577-021-00563-6.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3384_CR53","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41590-024-01843-8","volume":"25","author":"X Lan","year":"2024","unstructured":"Lan X, Mi T, Alli S, Guy C, Djekidel MN, Liu X, et al. Antitumor progenitor exhausted CD8\u2009+\u2009T cells are sustained by TCR engagement. Nat Immunol. 2024;25(6):1046\u201358. https:\/\/doi.org\/10.1038\/s41590-024-01843-8.","journal-title":"Nat Immunol"},{"issue":"5","key":"3384_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"K Hanada","year":"2022","unstructured":"Hanada K, Zhao C, Gil-Hoyos R, Gartner JJ, Chow-Parmer C, Lowery FJ, et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell. 2022;40(5):479\u2013e4936. https:\/\/doi.org\/10.1016\/j.ccell.2022.03.012.","journal-title":"Cancer Cell"},{"issue":"9","key":"3384_CR55","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13\u2009+\u2009T cells to immune-checkpoint blockade. Nat Cancer. 2022;3(9):1123\u201336. https:\/\/doi.org\/10.1038\/s43018-022-00433-7.","journal-title":"Nat Cancer"},{"issue":"7517","key":"3384_CR56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"22","key":"3384_CR57","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332. https:\/\/doi.org\/10.18632\/oncotarget.9076.","journal-title":"Oncotarget"},{"issue":"3","key":"3384_CR58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8\u2009+\u2009T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","journal-title":"Nat Immunol"},{"issue":"16","key":"3384_CR59","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8\u2009+\u2009T cells to promote antitumor immunity. Cell. 2024;187(16):4373\u2013e438815. https:\/\/doi.org\/10.1016\/j.cell.2024.06.036.","journal-title":"Cell"},{"issue":"4","key":"3384_CR60","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30(4):1023\u201334. https:\/\/doi.org\/10.1038\/s41591-024-02877-z.","journal-title":"Nat Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03384-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:02Z","timestamp":1792096922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03384-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3384"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03384-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of Zhongshan Hospital, Fudan University, with the approval number B2023-229. Written informed consent was obtained from each patient included. The results of TCGA cohort here are in whole or part based upon data generated by the TCGA Research Network (\n                      \n                      ). The Yonsei and ICB cohort data are derived from open-access, freely downloadable public datasets (GSE84437 and PRJEB25780). The use of data from public databases was granted an exemption from ethics approval by the Ethical Committee of Zhongshan Hospital, Fudan University.","order":3,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"285"}}